VTRS Stock Cash Flow Statements

Viatris Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Viatris Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-27	2020-06-28	2020-03-29

cash flows from operating activities:
net income																				-169,100,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	678,300,000	664,700,000	746,200,000	669,700,000	786,300,000	691,000,000	644,400,000	679,400,000	686,700,000	730,000,000	869,800,000	699,500,000	722,300,000	736,000,000	749,800,000	1,017,100,000	1,317,100,000	1,422,500,000
share-based compensation expense	37,100,000	55,200,000	32,300,000	32,400,000	34,700,000	46,700,000	55,800,000	43,100,000	39,200,000	42,600,000	29,600,000	29,100,000	29,400,000	28,300,000	22,500,000	25,000,000	31,000,000	32,700,000
deferred income tax benefit	-47,500,000	-43,600,000	-248,900,000	-312,400,000	-154,400,000	-51,900,000		-85,000,000	-68,200,000	-26,700,000
loss on disposal of business				107,400,000
acquired ipr&d	0	15,000,000	25,000,000	0	-7,500,000	-5,200,000
impairment of goodwill	0	2,936,800,000
other non-cash items	522,500,000	203,800,000	157,300,000	64,300,000	79,100,000	-3,000,000	647,500,000	-95,000,000	13,300,000	29,600,000	241,300,000	189,200,000	-34,000,000	37,800,000	123,600,000	84,700,000	170,200,000	33,300,000
litigation settlements and other contingencies	-27,600,000	-69,400,000	28,900,000	31,600,000	133,700,000	80,300,000	141,400,000	-48,300,000	-8,700,000	2,400,000	-7,600,000	-4,100,000	4,800,000	5,200,000	273,700,000	7,600,000	19,500,000	22,900,000
changes in operating assets and liabilities:
accounts receivable	-9,600,000	168,000,000	300,500,000	-33,000,000	22,800,000	9,800,000	81,400,000	-72,000,000	-145,800,000	215,000,000	-339,200,000	241,200,000	-26,800,000	-115,500,000	-9,800,000	183,800,000	-54,900,000	-59,800,000
inventories	-39,000,000	-193,700,000	-35,600,000	-129,000,000	-188,400,000	-370,400,000	-127,600,000	-219,200,000	-115,400,000	-151,100,000	180,100,000	-169,500,000	-201,000,000	-69,100,000	-76,500,000	-10,100,000	-137,600,000	-203,400,000
accounts payable	-291,300,000	101,600,000		-66,000,000	-231,600,000	287,900,000		43,600,000	9,300,000	183,400,000		-329,900,000	284,700,000	-30,200,000		-54,900,000	-245,400,000	191,900,000
income taxes	-246,000,000	-120,600,000	-67,600,000	268,200,000	21,000,000	-2,300,000	-47,100,000	-7,500,000	31,800,000	-53,900,000	-4,200,000	11,700,000	-49,200,000	67,000,000	-24,300,000	-337,600,000	-832,300,000	494,600,000
other operating assets and liabilities	-396,400,000	-177,200,000	-88,300,000	98,500,000	-49,000,000	-111,800,000	-261,900,000	263,400,000	-191,300,000	-224,800,000	-483,500,000	-130,600,000	-136,900,000	132,700,000	-266,900,000	-306,100,000	261,100,000	-354,600,000
net cash from operating activities	219,700,000	535,500,000	482,700,000	826,500,000	379,100,000	614,600,000	479,400,000	834,100,000	514,900,000	971,200,000	142,600,000	869,000,000	802,500,000	1,138,500,000	523,100,000	1,085,600,000	559,400,000	848,800,000	1,230,800,000
cash flows from investing activities:
cash paid for acquisitions, net of cash acquired			0	0	0	-350,000,000		0	0	-667,700,000
capital expenditures	-52,900,000	-42,600,000	-140,400,000	-77,000,000	-58,800,000	-49,800,000	-165,500,000	-95,900,000	-67,800,000	-47,800,000	-153,700,000	-103,900,000	-83,900,000	-64,500,000	-197,400,000	-121,000,000	-89,300,000	-49,500,000
free cash flows	166,800,000	492,900,000	342,300,000	749,500,000	320,300,000	564,800,000	313,900,000	738,200,000	447,100,000	923,400,000	-11,100,000	765,100,000	718,600,000	1,074,000,000	325,700,000	964,600,000	470,100,000	799,300,000
purchase of marketable securities	-6,300,000	-4,600,000	-4,300,000	-8,400,000	-5,600,000	-7,700,000	-5,400,000	-4,300,000	-7,600,000	-9,000,000	-6,900,000	-10,100,000	-4,600,000	-8,600,000	-3,900,000	-6,800,000	-7,200,000	-12,300,000
proceeds from the sale of marketable securities	6,300,000	4,600,000	4,300,000	8,400,000	5,600,000	7,700,000	5,400,000	4,300,000	7,600,000	9,000,000	6,900,000	10,200,000	4,300,000	8,500,000	3,800,000	6,800,000	6,900,000	12,300,000
payments for product rights and other	-1,200,000	-18,800,000	-700,000	-8,400,000	-10,700,000	-1,000,000	-35,400,000	-6,200,000	-21,200,000	-34,700,000	-12,200,000	-11,800,000	-5,600,000	-7,400,000	-24,000,000	-10,900,000	-13,600,000	-3,700,000
(purchases) refunds of ipr&d	0	-15,000,000
proceeds from sale of assets and subsidiaries			-3,100,000	1,832,500,000	437,100,000	240,600,000									200,000	13,100,000
proceeds from the sale of property, plant and equipment	1,600,000	11,300,000		800,000	700,000	700,000
net cash from investing activities	-52,500,000	-65,100,000	-168,700,000	1,747,900,000	375,800,000	-154,300,000	115,800,000	-53,800,000	-76,600,000	-749,500,000	1,784,500,000	-115,000,000	-82,100,000	-66,900,000	-219,100,000	-118,200,000	-16,800,000	236,300,000	11,111,900,000	-1,400,000
cash flows from financing activities:
payments of long-term debt			-1,374,300,000	-1,537,700,000			-500,100,000	0	0	-750,100,000	-700,600,000	-1,174,900,000	-1,786,900,000	-100,000	-600,000	-1,950,000,000
purchase of common stock	-175,000,000	-175,400,000	0	0	0	-250,000,000	0	0	0	-250,000,000
change in short-term borrowings	0	1,400,000					100,000	-22,900,000	-181,500,000	204,600,000	-500,400,000	-519,300,000	364,400,000	-837,900,000	-214,000,000	406,400,000	1,263,600,000	-1,063,900,000
taxes paid related to net share settlement of equity awards	-200,000	-29,300,000	0	-21,200,000	-3,400,000	-28,700,000	-5,600,000	-2,600,000	0	-30,000,000	-3,900,000	-200,000	-3,300,000	-9,900,000	-300,000	-3,600,000	-5,700,000	-7,800,000
contingent consideration payments	-1,700,000	-11,400,000	0	0	-20,600,000	-10,900,000	0	0	0	-8,400,000	0	0	-3,400,000	-15,500,000	0	0	-2,600,000	-26,000,000
payments of financing fees			0				-200,000				-300,000	-300,000	-900,000	-400,000	-500,000	-6,300,000
cash dividends paid	-139,800,000	-143,300,000	-143,300,000	-143,200,000	-145,500,000	-142,800,000	-144,000,000	-143,900,000	-143,900,000	-143,800,000	-145,500,000	-145,500,000	-145,500,000	-145,100,000	-133,000,000	-133,000,000
issuance of common stock	700,000	600,000	600,000	600,000	700,000	600,000	600,000	800,000	800,000	900,000	800,000	1,800,000
other items	-45,400,000	-109,600,000	98,300,000	68,100,000	122,600,000	6,200,000	-277,200,000	71,300,000	21,100,000	11,800,000	19,200,000	-400,000	0	-200,000	-800,000	-1,000,000	-1,000,000	-2,100,000
net cash from financing activities	-362,400,000	-467,000,000	-1,420,200,000	-1,636,700,000	-847,900,000	-425,600,000	-926,100,000	-97,600,000	-303,500,000	-974,700,000	-1,330,600,000	-758,700,000	-779,600,000	-1,009,000,000	-349,200,000	-877,500,000	-685,500,000	-1,099,800,000	-12,017,700,000	400,000
effect on cash of changes in exchange rates	6,700,000	16,800,000	-37,800,000	23,900,000	-4,400,000	-12,400,000	12,700,000	-2,300,000	-14,100,000	1,200,000	15,600,000	-14,300,000	-28,800,000	-11,400,000	-10,300,000	-7,300,000	8,900,000	-22,200,000
net decrease in cash, cash equivalents and restricted cash												-19,000,000
cash, cash equivalents and restricted cash — beginning of period	0	736,100,000	0	0	0	993,600,000	0	0	0	1,262,500,000	0	0	0	706,200,000	0	0	0	850,000,000
cash, cash equivalents and restricted cash — end of period	-188,500,000	756,300,000	-1,144,000,000	961,600,000	-97,400,000	1,015,900,000	-318,200,000	680,400,000	120,700,000	510,700,000	612,100,000	-19,000,000	-88,000,000	757,400,000	-55,500,000	82,600,000	-134,000,000	813,100,000
net earnings		-3,042,000,000	-516,500,000	94,800,000	-326,400,000	113,900,000	-765,600,000	331,600,000	264,000,000	224,700,000	1,011,200,000	354,300,000	313,900,000	399,200,000	-263,800,000	311,500,000	-279,200,000	-1,037,600,000
adjustments to reconcile net earnings to net cash from operating activities:
gain on disposal of business		36,900,000				-70,400,000
net increase in cash, cash equivalents and restricted cash		20,200,000	-1,144,000,000			22,300,000	-318,200,000			-751,800,000				51,200,000	-55,500,000			-36,900,000
trade accounts payable
proceeds from sale of property, plant and equipment							600,000	300,000			400,000	600,000			2,200,000	600,000
purchases of ipr&d
proceeds from issuance of long-term debt											100,000	1,080,100,000	795,300,000	100,000	0	810,000,000			-10,494,700,000	-200,000
non-contingent payments for product rights							0	0	0	-9,700,000					0	0
supplemental disclosures of cash flow information —
cash paid during the period for:
interest
refunds (purchases) of ipr&d				0
refund of ipr&d						5,200,000
deferred income tax expense															-52,900,000	147,000,000	293,200,000	288,400,000
income from equity method investments														-100,000	9,700,000	17,600,000	16,700,000	17,900,000
cash (paid) received for acquisitions, net of cash acquired
proceeds from the sale of assets and subsidiaries
gain from equity method investments
proceeds from the sale of assets										700,000				5,100,000				12,500,000
cash received (paid) for acquisitions, net of cash acquired
proceeds from exercise of stock options
non-cash transactions:
common stock issued for the combination
deferred income tax (benefit) expense												-21,900,000	-104,800,000	-52,800,000
cash received from acquisitions																0	0	277,000,000
write off of financing fees
purchase of ordinary shares
acquisition of noncontrolling interest
operating activities
amortization of bond discount and issuance costs																				2,800,000
currency remeasurement loss on euro notes
benefit for taxes on income
other changes in assets and liabilities																				72,100,000
investing activities
net																				-1,400,000
financing activities
long-term debt issuance costs paid																				-21,400,000
financing activities with pfizer
effect of exchange-rate changes on cash and cash equivalents
net increase/(decrease) in cash and cash equivalents
cash and cash equivalents, beginning
cash and cash equivalents, end
supplemental cash flow information
other adjustments
other changes in assets and liabilities:

We provide you with 20 years of cash flow statements for Viatris stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Viatris stock. Explore the full financial landscape of Viatris stock with our expertly curated income statements.

The information provided in this report about Viatris stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.